Published in J Am Heart Assoc on June 18, 2015
Phase III Acute Coronary Syndrome (APPRAISE-2) | NCT00831441
Age is not associated with intracranial haemorrhage in patients with mild traumatic brain injury and oral anticoagulation. J Negat Results Biomed (2016) 0.75
Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2009) 18.03
Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2007) 17.85
Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med (2011) 4.81
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med (2012) 4.49
Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med (2012) 4.10
Risk factors for intracerebral hemorrhage in the general population: a systematic review. Stroke (2003) 3.56
Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med (2011) 3.20
The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale. Am Heart J (2009) 1.16
The association between cerebral amyloid angiopathy and intracerebral haemorrhage: systematic review and meta-analysis. J Neurol Neurosurg Psychiatry (2011) 1.10
Prediction of 30-day mortality among patients with thrombolysis-related intracranial hemorrhage. Circulation (1998) 0.98
Prognostic significance of bleeding location and severity among patients with acute coronary syndromes. JACC Cardiovasc Interv (2013) 0.85
Reduction in overall occurrences of ischemic events with vorapaxar: results from TRACER. J Am Heart Assoc (2014) 0.77